T1	Outcomes 263 271	efficacy
T2	Outcomes 853 912	Aberrant Behavior Checklist-Community (ABC-C) Rating Scale.
T3	Outcomes 945 986	change in irritability subscale of ABC-C.
T4	Outcomes 1045 1070	observed for Irritability
T5	Outcomes 1104 1135	P < 0.001), Lethargy/Social
T6	Outcomes 1180 1199	P < 0.001), and
T7	Outcomes 1253 1280	P < 0.001), but not for
T8	Outcomes 1320 1355	97.424) = 1.469, P = 0.232)
T9	Outcomes 1484 1504	showed significantly
T10	Outcomes 1513 1577	improvement in the Irritability (P < 0.001), Lethargy/Social
T11	Outcomes 1589 1684	(P < 0.001), and Stereotypic Behavior (P < 0.00) but not in Hyperactivity/Noncompliance
T12	Outcomes 1705 1741	Inappropriate Speech (P = 0.802)
T13	Outcomes 1878 1891	the celecoxib
T14	Outcomes 2025 2081	of risperidone and celecoxib was superior to risperidone
